Skip to main content
      While post-CAR-T CRS might be semi-familiar for rheumatologists, ICANS is a new concept to get our heads around, and one

      David Liew drdavidliew

      4 months ago
      While post-CAR-T CRS might be semi-familiar for rheumatologists, ICANS is a new concept to get our heads around, and one which is far from heterogenous. @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/qX2jKMG2oB
      @CarolineDiorio @ChildrensPhila @RheumNow Indeed, there are a lot of familiar HLH/MAS friends in the post-CAR-T CRS mix.

      David Liew drdavidliew

      4 months ago
      @CarolineDiorio @ChildrensPhila @RheumNow Indeed, there are a lot of familiar HLH/MAS friends in the post-CAR-T CRS mix... (indeed, rheum friends from many places) @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/OzWu3MV1FA
      Another toxicity signal to watch in the CAR T space: LICATs
      Abstract 1537 reports a new immune-related toxicity distinct

      Akhil Sood MD, MS AkhilSoodMD

      4 months ago
      Another toxicity signal to watch in the CAR T space: LICATs Abstract 1537 reports a new immune-related toxicity distinct from CRS or ICANS: 🔹Affects organs prev involved in autoimmune dx: skin (35%) and kidneys (22%) 🔹Mostly mild (Grade 1–2); 3 cases Grade 3 @RheumNow #ACR25 https://t.co/mtZh47nWtv
      I've always (very) simplistically considered post-CAR-T CRS and HLH/MAS in the same bucket, and there certainly are subs

      David Liew drdavidliew

      4 months ago
      I've always (very) simplistically considered post-CAR-T CRS and HLH/MAS in the same bucket, and there certainly are substantial similarities. It raises the obvious question - can we borrow therapies? @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/2HkHxpl89u
      What dictates how severe CRS is following CAR-T?
      (Often the critical question, and will especially be in the autoimmune

      David Liew drdavidliew

      4 months ago
      What dictates how severe CRS is following CAR-T? (Often the critical question, and will especially be in the autoimmune space, where CAR-T is largely less time-critical) @CarolineDiorio @ChildrensPhila in the #ACR25 BCRC pre-meeting @RheumNow https://t.co/u0w4lx7YVn
      @CarolineDiorio @ChildrensPhila eloquently told the #ACR25 BCRC pre-meeting about the lessons they've learned about CRS

      David Liew drdavidliew

      4 months ago
      @CarolineDiorio @ChildrensPhila eloquently told the #ACR25 BCRC pre-meeting about the lessons they've learned about CRS and ICANS, the major CAR-T toxicities. Many questions still to answer, but they've also understood a lot we can learn from. @RheumNow https://t.co/Jhk1eCLpD4
      CAR-T toxicity in hematology
      (the things we have to look out for in rheumatology, as application of CAR-T potentially br

      David Liew drdavidliew

      4 months ago
      CAR-T toxicity in hematology (the things we have to look out for in rheumatology, as application of CAR-T potentially broadens) @andrew02114 @MGHCancerCenter with the heme-onc point of view in the #ACR25 BCRC @RheumNow https://t.co/1YjadL7LCF
      Andrew Yee @andrew02114 of @MGHCancerCenter details out how quickly the CAR-T paradigm changed in myeloma/lymphoma - fro

      David Liew drdavidliew

      4 months ago

      Andrew Yee @andrew02114 of @MGHCancerCenter details out how quickly the CAR-T paradigm changed in myeloma/lymphoma - from newsworthy to routine. Now that much more about CAR-T has been worked out, will adoption be quicker in autoimmune disease? #ACR25 BCRC pre-meeting @RheumNow https://t.co/oNuPXCwWQ9

      #SLE #DORIS #remission is RARE and without #prednisone even rarer

      #ASIA #Pacific 5K pts over 10 yrs

      A call to do bett

      Janet Pope Janetbirdope

      4 months ago
      #SLE #DORIS #remission is RARE and without #prednisone even rarer #ASIA #Pacific 5K pts over 10 yrs A call to do better 82% LLDAS, 70% remission, 31% GC-free remission (REM-0) at least once abst#595 @ACRheum @RheumNow #ACRBest https://t.co/OK6sYnqs81
      Rheum Now Rheumatology Round-Up — LIVE
      Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheu

      Dr. John Cush RheumNow

      4 months ago
      Rheum Now Rheumatology Round-Up — LIVE Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25. 📡 Live https://t.co/G6jKiHYVoR
      #Urinary #biomarkers #lupus #nephritis
      #Tenascin C -suggests repair, fibrosis, progress of #LN
      #IL16, #CD163, & mor

      Janet Pope Janetbirdope

      4 months ago
      #Urinary #biomarkers #lupus #nephritis #Tenascin C -suggests repair, fibrosis, progress of #LN #IL16, #CD163, & more for LN activity Sometime a biomarker may replace repeat #kidney #biopsies? #AMP group #Accelerated #Medicines #Program #ACR24 @ACRheum @RheumNow abst#851
      What to use in future for active #Sjogren's #SjD
      B cell depletion, signal attenuation
      Ianalumab 2+ phase3 RCTs
      Telitacep

      Janet Pope Janetbirdope

      4 months ago
      What to use in future for active #Sjogren's #SjD B cell depletion, signal attenuation Ianalumab 2+ phase3 RCTs Telitacept +RCT Nipocalimab FcRn +Ph2 Dazodalibep CD40L +Ph2 +RCTs HCQ+Lef Rituximab ?BTKi #ACR25 @ACRheum @RheumNow abst#LB24, LB11
      #MTX is NOT the same as TCZ in #GCA in RCT
      #TCZ did better

      So use an advanced Rx for GCA
      ex TCZ, Upa when approved
      MET

      Janet Pope Janetbirdope

      4 months ago
      #MTX is NOT the same as TCZ in #GCA in RCT #TCZ did better So use an advanced Rx for GCA ex TCZ, Upa when approved METOGiA RCT - more relapses in MTX abst#891 #ACR25 @ACRheum @RheumNow https://t.co/wsEKGF8dW2
      Will #PAD4 levels predict pts w #CCP positive #arthralgia who will develop #RA?
      Leeds study - 79 at risk pts
      PAD4 levels

      Janet Pope Janetbirdope

      4 months ago
      Will #PAD4 levels predict pts w #CCP positive #arthralgia who will develop #RA? Leeds study - 79 at risk pts PAD4 levels may predicting #rheumatoid #arthritis development #ACR25 @RheumNow @ACRheum abst#832 https://t.co/dnAA6z3NJQ
      ×